Wednesday, May 4, 2016

To Age or Not to Age, That is the Question
           
            You can run, but you can’t hide…eventually we will all age.  It’s just a matter of how we age that makes us different. There are those who age gracefully. As shown in a recent study, there is now a group of people known as “SuperAgers” whom are 80+ year old individuals that have memory function at a level equal to or greater than some who are 20-30 years old younger than them. (Gefen et. al.)  These folks seem to be sprinting away from age cognitively speaking. On the other hand, there are those who are stricken with Alzheimer’s disease and age in a cognitively degenerative manner. So the million-dollar question is what makes SuperAgers so different from those with Alzheimer’s, and how does one become a SuperAger?

What Makes A SuperAger Super
             In a recent study done by Tamar Gefen and colleagues at Northwestern University, they have found and characterized a group of people who have aged remarkable well when it comes to memory cognition. These people are what they call “SuperAgers.”  This cohort of 80-year-old individuals are cognitively functioning at the same level as 50 and 60 year olds when it comes to memory. This study revealed that there is a biological signature in the brains of SuperAgers. The structural features present in their brain show that they have a thicker anterior cingulate cortex in the right hemisphere. What makes the anterior cingulate so fascinating is that it indirectly functions on the “emotional” limbic system and the “cognitive” prefrontal cortex.  Thus the cingulate cortex is indirectly related to emotions such as motivation, perseverance, and cognitive function, while also being indirectly related to episodic memory. (Gefen et. Al.)

Why is a thicker cingulate cortex better?
            First of, the biggest risk factor in causing thinning of the cingulate cortex is the neurodegenerative characteristics seen in patients with Alzheimer’s. Alzheimer’s can be generally described as drastic memory impairment in all aspects of life, as a result of an accumulation of amyloid plaques and neurofibrillary tangles in the brain. Usually before getting Alzheimer’s patients go through a phase where the amyloid plaques and neurofibrillary fibers appear sparsely in memory regions of the brain, but do not result in memory impairment. Throughout time cells associated with plaques and tangles begin to die and these neurons do not connect their action potential to other neurons involved in memory. Thus memory impairment begins. For the SuperAgers, there was very little evidence of this cortical atrophy which is usually seen in most people their age.  As one gets older, it is assumed that with the normal accumulation of plaques and cell death, the cingulate cortex would thin out a bit. What is special about SuperAgers is that they do not have or have very little of these plaques and tangles, and thus have retained their cortical thickness; which is speculated to be a contributing factor in their preserved cognitive function.Gefen showed us that the thicker cingulate cortex lacked the characteristics of Alzheimer's, and thus that is why the cingulate cortex was thicker, but what about the people with Alzheimer's who have the thinner cingulate cortex? 
Attack the Amyloid Plaque
            On top of the study done by Gefen et al. at Northwestern University, Dr. Frank Longo, chairman of the neurology and neurological studies at Stanford University, has developed a knew drug known as LM11A-31, in the hopes that it will alleviate some of the symptoms of Alzheimer’s.  In the Time Magazine article, Alzheimer’s From A New Angle, Alice Park explains to us Dr. Longo’s new approach. As mentioned earlier, Alzheimer’s is characterized by an accumulation of amyloid plaques and neurofibrillary tangles in the brain.  
While, mostly scientists have been trying to get rid of the excess amyloid in the brain before it can form plaques and cause neural damage, Dr. Longo’s drug, LMA11-31, is focused on keeping brain cells strong, and protected against neurological vampires such as the amyloid plaques. (Park) How amyloid plaques work is that they choke off the nutrients to other neural cells, and when these cells don’t get the sustenance they need they begin to die slowly, and accumulate as “neurological garbage." (Park)  The way the drug functions is by blocking receptor p75 that sits on the extracellular membranes of neuron cells, and thus interrupts a cascade of events where cells are signaled to die. Dr. Longo, however, is not naïve into thinking that this drug alone will do the job, LMA11-31 needs a helper, and this is where the work done by the other scientists has come into play.
 A New Perspective
            As explained in the Time article, scientists have begun to think that the amyloid plaques are the initial trigger, and that the tau protein is the silver bullet. (Park) Tau is a protein that stabilized microtubules and when it begins to degrade language and memory organization begin to fail. In the same article, Dr. William Jagust, a professor of neuroscience and public health at the University of California Berkley, explains to us that he believes Alzheimer’s occurs in two stages: 1) Amyloid accumulation and 2) degradation of tau. If there could be a treatment that attacks the plaque-- as many  have already done--in combination with Dr. Longo’s new drug that keeps the cells healthy, and a drug to keep tau from breaking down, then maybe scientists could be close to curing Alzheimer’s.

Is the damage of Alzheimer’s reversible?
Furthermore, in a recent study by scientists at Rush University Alzheimer’s Center they have found evidence that patients with high levels of the nerve growth factor BDNF retain more of their cognitive brain function even when amyloid build up has already begun. (Park) While there is no drug to boost BDNF levels yet, it seems that researchers at Rush are very intrigued on finding out if higher levels of growth factors could allow people to retain some of their cognitive function or even counteract the effects of the plaque.

What would Gefen say?
In the Northwestern study done by Gefen et al, they proclaimed that the cingulate cortical thickness has been preserved because it lacked the amyloid plaques and neurofibrillary tangles that lead to cingulate atrophy. Thus, the thicker cingulate cortex was able to function more effectively for the memory cognition of the SuperAgers. Gefen acknowledges that her SuperAgers seem to lack the aging brain signature, but did not know why. What is clear is that research, such as Dr. Longo’s, can shed some new light on preserving the cingulate cortex. It can be inferred from both studies, that if the cingulate cortex is preserved and strengthened then maybe one day we can all become SuperAgers.

Bibliography

Park, Alice. "Alzheimer's from a New Angle." Time. Time, 11 Feb. 2016. Web. 04 May 2016.
Time Magazine link:

Gefen, Tamar, Melanie Peterson, Steven T. Papastefan, Adam Martersteck, Kristen Whitney, Alfred Rademaker, Eileen H. Bigio, Sandra Weintrab, Emily Rogalski, Marsel Mesulum, and Changuz Geula. "The Journal of Neuroscience." Morphometirc and Histologic Substrates of Cingulate Integrity in Elders with Exceptional Memory Capacity (2015): n. pag. Web. 3 May 2016.

Images:



No comments:

Post a Comment